<DOC>
	<DOCNO>NCT01211457</DOCNO>
	<brief_summary>This open label , phase I/II study evaluate safety efficacy sapacitabine administer alternate cycle decitabine elderly patient newly diagnose Acute Myeloid Leukemia ( AML ) .</brief_summary>
	<brief_title>Study Sapacitabine Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Newly diagnose AML base WHO classification Age 70 year old treatment choice lowintensity therapy investigator assessment refuse intensive induction therapy recommend investigator ECOG performance status 02 Adequate renal function Adequate liver function Able swallow capsule Ability understand willingness sign inform consent form AML subtype acute promyelocytic leukemia extramedullary myeloid tumor without bone marrow involvement Having receive systemic anticancer therapy AML receive treatment hypomethylating agent cytotoxic chemotherapy precede MDS MPD Known central nervous system ( CNS ) involvement leukemia Uncontrolled intercurrent illness include Known hypersensitivity decitabine Known HIVpositive</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>